Implant Confidently
The Regent™ aortic mechanical valve offers surgeon-friendly implantability, featuring a low valve implant height that helps ensure coronary ostia clearance. Two distinct cuff types—FlexCuff™ or Standard Cuff—provide you with different options. The Regent™ valve features exceptional hemodynamics in small aortic root patients.1*
Because prosthesis-patient mismatch (PPM) can be problematic in the aortic position, Abbott designed the Regent™ valve specifically to avoid this issue. The orifice-to-annulus ratio of the Regent™ valve ensures large effective orifice areas (EOAs) and reduces PPM.2
The Regent™ valve shows low thromboembolism, thrombosis, and bleeding over a wide international normalized ratio (INR) range, making this valve an excellent choice.3-6
*Measured one year post-surgery.
Learn about the features of the Regent™ Aortic Mechanical Heart Valve.
Confidently Implant the Most Trusted Mechanical Valves in the World.
Ordering Information
Regent™ Aortic Mechanical Heart Valve
| Catalog Number | Tissue Annulus Diameter (mm) | Geometric Orifice Area (cm²) | Implant Height Open (mm) | Overall Height Open (mm) | Cuff Outer Diameter (mm) |
|---|---|---|---|---|---|
| Standard Cuff | |||||
| 17 AGN-751* | 17 | 1.9 | 5.1 | 10.5 | 22.5 |
| 19 AGN-751 | 19 | 2.4 | 5.9 | 11.4 | 24.5 |
| 21 AGN-751 | 21 | 2.9 | 6.7 | 12.7 | 26.5 |
| 23 AGN-751 | 23 | 3.5 | 7.3 | 13.9 | 28.5 |
| 25 AGN-751 | 25 | 4.0 | 7.6 | 14.1 | 30.5 |
| 27 AGN-751 | 27 | 4.7 | 8.4 | 14.9 | 32.5 |
| 29 AGN-751* | 29 | 5.4 | 9.1 | 16.2 | 34.5 |
| FlexCuff™ | |||||
| 17 AGFN-756* | 17 | 1.9 | 5.1 | 10.5 | 24.0 |
| 19 AGFN-756 | 19 | 2.4 | 5.9 | 11.4 | 25.5 |
| 21 AGFN-756 | 21 | 2.9 | 6.7 | 12.7 | 28.5 |
| 23 AGFN-756 | 23 | 3.5 | 7.3 | 13.9 | 31.0 |
| 25 AGFN-756 | 25 | 4.0 | 7.6 | 14.1 | 32.5 |
| 27 AGFN-756 | 27 | 4.7 | 8.4 | 14.9 | 34.5 |
| 29 AGFN-756* | 29 | 5.4 | 9.1 | 16.2 | 36.5 |
*Sizes 17 and 29 are not available in all geographies.
References
- Regent PMA Supplement.
- Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol. 2000;36(4):1131-1141. doi.org/10.1016/s0735-1097(00)00859-7.
- Bach DS, Sakwa MP, Goldbach M, et al. Hemodynamics and early clinical performance of the St. Jude Medical Regent mechanical aortic valve. Ann Thorac Surg. 2002;74(6):2003-2009.
- Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am Heart J. 2010;160(1); 171-178. doi: 10.1016/j.ahj.2010.05.005
- Koertke H, Zittermann A, Wagner O, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Ann Thorac Surg. 2010;90(5):1487-1493.
- Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg. 2005;79(3):776-82. doi: 10.1016/j.athoracsur.2004.08.047
MAT-2011658 v2.0